Novel markers of squamous differentiation in the urinary bladder
Wenbin Huang(Nanjing Medical University), Liang Cheng(University of North Carolina at Chapel Hill), Sean R. Williamson(Wayne State University), Robert E. Emerson(Indiana University – Purdue University Indianapolis), Qiu Rao(Indiana University School of Medicine), David J. Grignon(Indiana University School of Medicine), Antonio López-Beltrán(Cordoba University), Muhammad T. Idrees(Indiana University School of Medicine), Rodolfo Montironi(Marche Polytechnic University), John N. Eble(Indiana University School of Medicine), Michael O. Koch, Ming‐Sheng Wang(Indiana University School of Medicine), Lee Ann Baldridge(Indiana University School of Medicine), Xiao-jun Zhou(Nanjing University), Shaobo Zhang(Indiana University – Purdue University Indianapolis), Noah M. Hahn(Indiana University Health)
Cited by 45
Related Papers
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
|Journal of Clinical Oncology|2011|686